Teva's Generics CEO Departure Cause for Concern
Pricing pressure in the generic drug market and anticipated generic competition on the one of the narrow-moat company's main drugs in 2017 makes the abrupt leadership change a concerning development at a critical time for the company.
Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.